TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19228761

Group type: EXPERIMENTAL
Intervention: Endometrial secretion cytokine profiling (MCP-1)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Endometrial secretion cytokine profiling (IP-10)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Endometrial secretion cytokine profiling (IL-1beta)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Endometrial secretion cytokine profiling (TNF-alpha)
Number of subjects: 210
Study: 19228873

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obese subjects
Number of subjects: 0
Study: 19234987

Group type: EXPERIMENTAL
Intervention: Team-based pharmacist care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integration of pharmacists into the teams
Number of subjects: 0
Study: 19237390

Group type: EXPERIMENTAL
Intervention: Salmeterol monotherapy for 2 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination therapy with salmeterol and fluticasone for 2 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Salmeterol effects on BDNF release by human peripheral blood mononuclear cells
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Salmeterol monotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Beta(2)-receptor polymorphisms
Number of subjects: 18
Study: 19238148

Group type: EXPERIMENTAL
Intervention: Selective CDK inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDK1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interphase CDKs
Number of subjects: 0
Study: 19238149

Group type: EXPERIMENTAL
Intervention: Targeted therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 19240154

Group type: EXPERIMENTAL
Intervention: Severely burned pediatric patients
Number of subjects: 194

Group type: COMPARATOR
Intervention: Nonburned, noninjured children
Number of subjects: 194
Study: 19245711

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 5000
Study: 19245964

Group type: EXPERIMENTAL
Intervention: Insulin resistance (IR) defined by Fasting Insulin Resistance Index (FIRI) > or = 2.7
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Insulin resistance (IR) defined by FIRI > or = 2.7
Number of subjects: 129

Group type: COMPARATOR
Intervention: Reactive hyperemia peripheral arterial tonometry (RH-PAT) testing
Number of subjects: 129
Study: 19246107

Group type: EXPERIMENTAL
Intervention: High pulse pressure
Number of subjects: 427
Study: 19254128

Group type: EXPERIMENTAL
Intervention: Salivary biomarkers (MMP-8, MMP-9, osteoprotegerin) and pathogen biofilm values (T. denticola)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Salivary biomarkers and pathogen biofilm values
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Salivary MMP-8 and T. denticola biofilm levels
Number of subjects: 100
Study: 19254204

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) epoetin beta
Number of subjects: 4264

Group type: COMPARATOR
Intervention: Intravenous (IV) epoetin beta
Number of subjects: 4264
Study: 19254938

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR) program, 8 weeks of group instruction, home practice, and telephone monitoring
Number of subjects: 150

Group type: COMPARATOR
Intervention: Health Education program (time and attention control)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Waitlist arm (6 months wait before re-randomization)
Number of subjects: 150
Study: 19255017

Group type: EXPERIMENTAL
Intervention: Caspofungin 70 mg/m(2) on day 1, followed by 50 mg/m(2) per day (maximum: 70 mg/day) for 2 to 87 days
Number of subjects: 49
Study: 19257800

Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 300/10 mg
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 300/10 mg (in stage 2 hypertension subgroup)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 150/5 mg
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Add-on hydrochlorothiazide (HCT)
Number of subjects: 556
Study: 19261173

Group type: EXPERIMENTAL
Intervention: Intradermal influenza vaccination
Number of subjects: 5543

Group type: COMPARATOR
Intervention: Intramuscular influenza vaccination
Number of subjects: 5543
Study: 19262209

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg and Pioglitazone 30 mg daily for 6 months
Number of subjects: 25
Study: 19264677

Group type: EXPERIMENTAL
Intervention: R2* magnetic resonance imaging (R2*-MRI)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ferritin
Number of subjects: 43
Study: 19264750

Group type: EXPERIMENTAL
Intervention: Biventricular pacemakers without a back-up defibrillator (CRT-P)
Number of subjects: 198
Study: 19264884

Group type: EXPERIMENTAL
Intervention: Pattern electroretinogram (PERG)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Visual field (VF) sensitivity loss
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: OCT and PERG parameters
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Macular and RNFL thickness parameters
Number of subjects: 41
Study: 19265088

Group type: EXPERIMENTAL
Intervention: Sputum cytologic atypia (moderate or worse)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sputum cytologic atypia (degree of atypia)
Number of subjects: 0
Study: 19265494

Group type: EXPERIMENTAL
Intervention: Fosbretabulin 45 mg/m² as a 10-minute intravenous infusion on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fosbretabulin 45 mg/m²
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Baseline serum sICAM levels
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Low baseline sICAM levels
Number of subjects: 26
Study: 19267708

Group type: EXPERIMENTAL
Intervention: 1 g TTA daily for 28 days
Number of subjects: 16
Study: 19268724

Group type: EXPERIMENTAL
Intervention: Ordinal regression model using demographic, clinical, and laboratory data
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: FIB-4 index ([age x AST]/[platelet count x (ALT)(1/2)])
Number of subjects: 173
Study: 19270751

Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m²/day for 5 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No fludarabine conditioning
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 10
Study: 19273449

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 1250
Study: 19273480

Group type: EXPERIMENTAL
Intervention: Claims data
Number of subjects: 4020

Group type: EXPERIMENTAL
Intervention: Survey data
Number of subjects: 4020

Group type: EXPERIMENTAL
Intervention: Combined claims and survey data
Number of subjects: 4020
Study: 19273678

Group type: EXPERIMENTAL
Intervention: Famciclovir (approximately 12.5 mg/kg for children < 40 kg and 500 mg for children ≥ 40 kg)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Famciclovir (twice a day for HSV; three times a day for VZV)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Famciclovir (7-day dosing regimen)
Number of subjects: 151
Study: 19273786

Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 35
Study: 19273881

Group type: EXPERIMENTAL
Intervention: IUCS
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional in vitro culture
Number of subjects: 13
Study: 19273870

Group type: EXPERIMENTAL
Intervention: Illness self-management intervention delivered by home visits or telephone calls
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Personality variables added to the missing data prediction model
Number of subjects: 415
Study: 19277123

Group type: EXPERIMENTAL
Intervention: prGCD (60 Units/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: prGCD (300 Units/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: prGCD (up to 60 Units/kg)
Number of subjects: 6
Study: 19277125

Group type: EXPERIMENTAL
Intervention: 5-MTHF and vitamin B12 supplementation (7.5 mg/day of 5-MTHF and 0.5 mg/day of vitamin B12) for 24 weeks
Number of subjects: 31
Study: 19277602

Group type: EXPERIMENTAL
Intervention: lifestyle modification plus pioglitazone, 30 mg (n = 204)
Number of subjects: 407

Group type: COMPARATOR
Intervention: lifestyle modification plus placebo (n = 203)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: lifestyle modification plus pioglitazone
Number of subjects: 407

Group type: COMPARATOR
Intervention: lifestyle modification plus placebo
Number of subjects: 407
Study: 19279303

Group type: EXPERIMENTAL
Intervention: Unattended polysomnography
Number of subjects: 306
Study: 19282318

Group type: EXPERIMENTAL
Intervention: Nasal lavage for upper airway (UAW) sampling
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Detection of S aureus or P aeruginosa in LAW specimens
Number of subjects: 182
Study: 19282789

Group type: EXPERIMENTAL
Intervention: Isolated limb infusion (ILI) with melphalan and dactinomycin
Number of subjects: 32
Study: 19284286

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a and ribavirin
Number of subjects: 341
Study: 19284416

Group type: EXPERIMENTAL
Intervention: Depletion of L-ascorbic acid (LAA) through a diet deficient in LAA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Supplementation of L-ascorbic acid (LAA) via daily intravenous administration
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: In vitro assay indicating sensitivity to LAA
Number of subjects: 18
Study: 19284881

Group type: EXPERIMENTAL
Intervention: Tifacogin
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study: 19286847

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Allopurinol 300 mg
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Febuxostat (both doses)
Number of subjects: 1086
Study: 19286996

Group type: EXPERIMENTAL
Intervention: miR-184
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antisense blocking of miR-184
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous transfection of precursor miR-184
Number of subjects: 0
Study: 19287552

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (2-20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 0
Study: 19289451

Group type: EXPERIMENTAL
Intervention: SSRI exposure (N=71)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Continuous depression (N=14)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Partial depression (N=22)
Number of subjects: 238

Group type: COMPARATOR
Intervention: No SSRI, no depression (N=131)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Depression exposure (N=36)
Number of subjects: 238
Study: 19292893

Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: Age at menarche (16 years or older)
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: Age at menopause (55 years or older)
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: Height and weight
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: Severe obesity (BMI 35 or more)
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: Positive family history of breast cancer
Number of subjects: 2085
Study: 19293071

Group type: EXPERIMENTAL
Intervention: Aspirin 75 to 162 mg/d
Number of subjects: 15595

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg or greater
Number of subjects: 15595

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 15595

Group type: EXPERIMENTAL
Intervention: Aspirin greater than 100 mg
Number of subjects: 15595

Group type: EXPERIMENTAL
Intervention: Aspirin greater than 100 mg with clopidogrel
Number of subjects: 15595

Group type: EXPERIMENTAL
Intervention: Aspirin 75 to 81 mg
Number of subjects: 15595
Study: 19297054

Group type: EXPERIMENTAL
Intervention: Insulin detemir therapy
Number of subjects: 0
Study: 19297344

Group type: EXPERIMENTAL
Intervention: New ASAS classification criteria for axial SpA
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Imaging arm of new ASAS criteria
Number of subjects: 649

Group type: COMPARATOR
Intervention: European Spondylarthropathy Study Group criteria modified for MRI
Number of subjects: 649

Group type: COMPARATOR
Intervention: Modified Amor criteria
Number of subjects: 649
Study: 19297571

Group type: EXPERIMENTAL
Intervention: Heart failure incidence in black women
Number of subjects: 5115

Group type: EXPERIMENTAL
Intervention: Heart failure incidence in black men
Number of subjects: 5115

Group type: EXPERIMENTAL
Intervention: Heart failure incidence in white women
Number of subjects: 5115

Group type: EXPERIMENTAL
Intervention: Heart failure incidence in white men
Number of subjects: 5115

Group type: COMPARATOR
Intervention: Higher diastolic blood pressure
Number of subjects: 5115

Group type: COMPARATOR
Intervention: Higher body-mass index
Number of subjects: 5115

Group type: COMPARATOR
Intervention: Lower high-density lipoprotein cholesterol
Number of subjects: 5115

Group type: COMPARATOR
Intervention: Kidney disease
Number of subjects: 5115

Group type: COMPARATOR
Intervention: Depressed systolic function
Number of subjects: 5115

Group type: COMPARATOR
Intervention: Borderline systolic function
Number of subjects: 5115
Study: 19299430

Group type: EXPERIMENTAL
Intervention: C-reactive protein levels 2 days after PCI
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: C-reactive protein levels
Number of subjects: 42
Study: 19301723

Group type: EXPERIMENTAL
Intervention: Non-mobilized peripheral blood angiogenic cell precursors (NMPB-ACPs) therapy
Number of subjects: 6
Study: 19303808

Group type: EXPERIMENTAL
Intervention: EBV DNA detection
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: HAdV DNA detection
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: CMV pp65 antigen detection
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Repeated EBV DNA detection
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Acute rejection
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: EBV DNA detection risk factors
Number of subjects: 385
Study: 19303970

Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention (130 children)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No intervention (50 children)
Number of subjects: 180
Study: 19304957

Group type: EXPERIMENTAL
Intervention: CEBPA mutations present
Number of subjects: 847

Group type: COMPARATOR
Intervention: No CEBPA mutations
Number of subjects: 847
Study: 19305337

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 143
Study: 19307014

Group type: EXPERIMENTAL
Intervention: Weekly topotecan 3.5 mg/m(2) and docetaxel 30 mg/m(2) for 3 consecutive weeks, repeated every 4 weeks for 6 cycles or until disease progression, unacceptable toxicity, or death.
Number of subjects: 27
Study: 19317608

Group type: EXPERIMENTAL
Intervention: HRQoL assessment using Short Form-36 (SF-36)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Fatigue Severity Scale (FSS)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: MS symptom scales for Cognition
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Correlation analysis of HRQoL with clinical measures
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Proposed MID for HRQoL measures
Number of subjects: 249
Study: 19317607

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg weekly
Number of subjects: 0
Study: 19317960

Group type: EXPERIMENTAL
Intervention: fMRI-guided rTMS treatment, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19323966

Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg daily titrated to 1 mg twice daily)
Number of subjects: 18
Study: 19324258

Group type: EXPERIMENTAL
Intervention: T-wave alternans (TWA) assessment using the modified moving average (MMA) method
Number of subjects: 1003
Study: 19324499

Group type: EXPERIMENTAL
Intervention: ASSIST total substance involvement (TSI) score
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: ASSIST cannabis SSI score (cutoff >/=2)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: ASSIST alcohol SSI score (cutoff >/=4)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: ASSIST amphetamine SSI score (cutoff >/=1)
Number of subjects: 214
Study: 19325447

Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 4004

Group type: COMPARATOR
Intervention: 7vCRM
Number of subjects: 4004
Study: 19325452

Group type: EXPERIMENTAL
Intervention: PHiD-CV coadministered with DTPa-[HBV]-IPV/Hib, DTPa-[HBV]-IPV, DTPw-HBV/Hib, IPV, OPV, Hib-MenC-TT, MenC-TT, MenC-CRM
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7vCRM coadministered with DTPa-[HBV]-IPV/Hib, DTPa-[HBV]-IPV, DTPw-HBV/Hib, IPV, OPV, Hib-MenC-TT, MenC-TT, MenC-CRM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster vaccination with PHiD-CV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PHiD-CV with childhood vaccines
Number of subjects: 0
Study: 19327956

Group type: EXPERIMENTAL
Intervention: Dalteparin thromboprophylaxis
Number of subjects: 0
Study: 19330248

Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass graft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass graft
Number of subjects: 20
Study: 19331677

Group type: EXPERIMENTAL
Intervention: Physical distress (3rd tertile)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Quality of life (3rd tertile)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Physical distress (in multivariate analysis)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Quality of life (in multivariate analysis)
Number of subjects: 433
Study: 19332630

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN; Enbrel)
Number of subjects: 14000
Study: 19332768

Group type: EXPERIMENTAL
Intervention: lenalidomide plus dexamethasone
Number of subjects: 130
Study: 19333404

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19335386

Group type: EXPERIMENTAL
Intervention: OROS-MPH
Number of subjects: 240

Group type: COMPARATOR
Intervention: IR-MPH
Number of subjects: 240
Study: 19336634

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 19336742

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.5 mg/m² on days 1, 4, 8, and 11, every 21 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 16
Study: 19339093

Group type: EXPERIMENTAL
Intervention: 6 treatments/week (daily trial)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 6 nocturnal treatments/week (nocturnal trial)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3 treatments/week (control for daily trial)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3 conventional treatments/week (control for nocturnal trial)
Number of subjects: 100
Study: 19339913

Group type: EXPERIMENTAL
Intervention: MTRR 66A>G genotype (MTRR 66AA, AG, GG)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: All groups (MTRR 66AA, AG, GG)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (wild-type patients)
Number of subjects: 140
Study: 19341509

Group type: EXPERIMENTAL
Intervention: Citalopram up to 60 mg/d for up to 14 weeks
Number of subjects: 2876
Study: 19344074

Group type: EXPERIMENTAL
Intervention: Children with corticotropinomas
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (parents)
Number of subjects: 20
Study: 19344390

Group type: EXPERIMENTAL
Intervention: Asymmetric dimethylarginine (ADMA) levels in patients with SCD
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Arginine to ADMA ratio in patients with homozygous SCD
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Correlation of ADMA with clinical variables
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Association of ADMA with pulmonary hypertension (PH)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: ADMA levels and early mortality
Number of subjects: 177
Study: 19345439

Group type: EXPERIMENTAL
Intervention: Telbivudine treatment
Number of subjects: 680
Study: 19348029

Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg once daily for 4 weeks, with possible escalation to 8 mg based on efficacy and tolerability assessment.
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Fesoterodine treatment satisfaction at week 12.
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Patient Perception of Bladder Condition (PPBC) at week 12.
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: OAB-q Symptom Bother and Health-Related Quality of Life (HRQL) scales at week 12.
Number of subjects: 516
Study: 19348685

Group type: EXPERIMENTAL
Intervention: Idraparinux (new long-acting anticoagulant drug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA)
Number of subjects: 0
Study: 19350213

Group type: EXPERIMENTAL
Intervention: Subcutaneous continuous glucose monitoring (CGMS) with norepinephrine therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Subcutaneous continuous glucose monitoring (CGMS) without norepinephrine therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subcutaneous continuous glucose monitoring (CGMS)
Number of subjects: 50
Study: 19353673

Group type: EXPERIMENTAL
Intervention: Image domain TGRAPPA reconstruction
Number of subjects: 0
Study: 19357147

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 40

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 40
Study: 19358725

Group type: EXPERIMENTAL
Intervention: abacavir sulfate/lamivudine/zidovudine (ABC/3TC/ZDV) twice-daily
Number of subjects: 279

Group type: COMPARATOR
Intervention: atazanavir (ATV) once-daily plus lamivudine/zidovudine (3TC/ZDV) twice-daily
Number of subjects: 279
Study: 19360102

Group type: EXPERIMENTAL
Intervention: Hormonal contraceptives
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Condom use
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Contraceptive use prior to screening
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Obstacles to contraceptive use
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Overall contraceptive use
Number of subjects: 103